Correlation Between Cystatin C and Coronary Artery Disease

Document Type: Original Article


Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, IR Iran.


Background: Coronary artery disease (CAD) is one of the most common complicated cardiovascular diseases causing morbidity and mortality. Early detection of CAD can help us choose the best therapeutic procedures and gain optimal results. This study aimed to evaluate cystatin C serum levels in patients with CAD.
Methods: This cross-sectional study was performed on 95 cases (60 in the CAD group and 35 in the control group). Cystatin C was measured via the enzymatic method and the sensitivity and specificity of cystatin C for diagnosing CAD were measured by ROC curve.
Results: The mean serum level of cystatin C was 2.21 ± 0.97 mg/L; it was higher among the patients with CAD (3.57 ± 0.58 mg/L). The area under the ROC curve was calculated to be 0.702, with sensitivity of 88.5% and specificity of 82.4% based on 0.5 as the best cutoff point for serum cystatin C (P = 0.001, 95% CI: 0.59 to 0.81).
Conclusions: Our results showed that cystatin C serum levels with a cutoff point of 0.5 had high and acceptable sensitivity and specificity in diagnosing CAD and could, thus, play an important role in the early diagnosis of CAD and prevention of adverse cardiovascular events.


1. Dickens C, Cherrington A, McGowan L.
Depression and health-related quality of life in
people with coronary heart disease: A
systematic review. Eur J Cardiovasc
Nurs. 2012;11:265–275.
2. Zwadlo C, Meyer GP, Schieffer B, WesthoffBleck M. Anomalous intramural course of
coronary arteries in congenital heart diseasethree case reports and review of the
literature. Congenit Heart Dis. 2012;7:139–144.
3. Mehra M, Somohano T, Choi M. Mandibular
fibular graft reconstruction with CAD/CAM
technology: A clinical report and literature
review. J Prosthet Dent. 2016;115:123–128.
4. WHO Fact sheet N°310. updated July 2013

5. de Hoog VC, Timmers L, Schoneveld AH,
Wang JW, van de Weg SM, Sze SK, et al.
Serum extracellular vesicle protein levels are
associated with acute coronary syndrome. Eur
Heart J Acute Cardiovasc Care 2013;2(1):53–
6. Reichlin T, Hochholzer W, Bassetti S, Steuer S,
Stelzig C, Hartwiger S, et al. Early diagnosis
ofmyocardial infarction with sensitive cardiac
troponin assays. N Engl JMed 2009;361(9):858–
7. Dharnidharka VR, Kwon C, Stevens G. Serum
cystatin C is superior to serum creatinine as a
marker of kidney function: a meta-analysis. Am
J Kidney Dis 2002; 40(2): 221-6
8. Grubb A, Bjork J, Lindstrom V, et al. A cystatin
C-based formula without anthropometric
variables estimates glomerular filtration rate
better than creatinine clearance using the
Cockcroft-Gault formula. Scand J Clin Lab
Invest 2005; 65(2): 153-62.
9. Grubb A, Nyman U, Bjork J, et al. Simple
cystatin C-based prediction equations for
glomerular filtration rate compared with the
modification of diet in renal disease prediction
equation for adults and the Schwartz and the
Counahan-Barratt prediction equations for
children. Clin Chem 2005; 51(8): 1420-31
10. Ix JH, Shlipak MG, Chertow GM, et al.
Association of cystatin C with mortality,
cardiovascular events, and incident heart failure
among persons with coronary heart disease: data
from the Heart and Soul Study. Circulation
2007; 115(2): 173-9
11. Kestenbaum B, Rudser KD, de Boer IH, et al.
Differences in kidney function and incident
hypertension: the multi-ethnic study of
atherosclerosis. Ann Intern Med 2008; 148(7):
12. Sarnak MJ, Katz R, Stehman-Breen CO, et al.
Cystatin C concentration as a risk factor for
heart failure in older adults. Ann Intern Med
2005; 142(7): 497-505.
13. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin
C and the risk of death and cardiovascular
events among elderly persons. N Engl J Med
2005; 352(20): 2049-60 doi:
10.1056/NEJMoa043161published Online First:
Epub Date.
14. Taglieri N, Fernandez-Berges DJ, Koenig W, et
al. Plasma cystatin C for prediction of 1-year
cardiac events in Mediterranean patients with
non-ST elevation acute coronary syndrome.
Atherosclerosis 2010; 209(1): 300-5.
15. Koc M, Batur MK, Karaarslan O, Abali G.
Clinical utility of serum cystatin C in predicting
coronary artery disease. Cardiol J
16. Ristiniemi N, Lund J, Tertti R, Christensson A,
Ilva T, Porela P, et al. Cystatin C as a predictor
of all-cause mortality and myocardial infarction
in patients with non-STelevation acute coronary
syndrome. Clin Biochem 2012;45(7–8):535–40.
17. Silva D, Cortez-Dias N, Jorge C, Marques JS,
Carrilho-Ferreira P, Magalhães A, et al. Cystatin
C as prognostic biomarker in ST-segment
elevation acute myocardial infarction. Am J
Cardiol 2012;109(10):1431–8.
18. Yan L1, Ding S2, Gu B1,2, Ma P1,2. Clinical
application of simultaneous detection of cystatin
C, cathepsin S, and IL-1 in classification
of coronary artery disease. J Biomed Res. 2017
Jul 13;31(4):315-320.
19. Sugiyama H1, Miyoshi T2, Osawa K1, Miki
T1, Koide Y1, Nakamura K1, Morita H3, Ito
H1. Serum cystatin C levels are associated
with coronary artery calcification in women
without chronic kidney disease. J Cardiol. 2017
20. Zhang J1, Wu X2, Gao P3, Yan P4.Correlations
of serum cystatin C and glomerular filtration
rate with vascular lesions and severity in
acute coronary syndrome. BMC Cardiovasc
Disord. 2017 Jan 31;17(1):47.
21. Wang Y1, Su X2, Zhang W2, Yang W2, Wang
Y2, He Y3. Correlation between serum cystatin
C level and elderly hypertensive patients
combined coronaryheart disease. Int J Clin Exp
Med. 2015 Apr 15;8(4):6287-90. eCollection
22. Negrusz-Kawecka M1, Poręba R2, Hulok
A1, Sciborski K1, Marczak J3, Bańkowski T4.
Evaluation of the significance of cystatin
C levels in patients suffering from coronary
artery disease. Adv Clin Exp Med. 2014 JulAug;23(4):551-8.
23. Wang GN1, Sun K1, Hu DL1, Wu HH1, Wang
XZ2, Zhang JS3. Serum cystatin C levels are
associated with coronary artery disease and its
severity. Clin Biochem. 2014 Nov;47(16-
24. Abdallah E, Waked E, Al-Helal B, Asad R,
Nabil M, Harba T. Novel troponin-like
biomarkers of acute kidney injury. Saudi J
Kidney Dis Transpl. 2013;24:1111–24.
25. Longenecker CT, Hileman CO, Funderburg NT,
McComsey GA. Rosuvastatin preserves renal
function and lowers cystatin C in HIV-infected
subjects on antiretroviral therapy: the SATURNHIV trial. Clin Infect Dis. 2014;59:1148–56.
26. Ganda A, Magnusson M, Yvan-Charvet L,
Hedblad B, Engström G, Ai D, et al. Mildrenal
dysfunction and metabolites tied to low HDL
cholesterol are associated with monocytosis and
atherosclerosis. Circulation. 2013;127:988–96.
27. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical
prognostic significance of plasma cystatin C
levels among patients with acute coronary
syndrome. Clin Cardiol. 2009;32:644–8.
28. 21. Negrusz-Kawecka M, Poręba R, Hulok A,
Sciborski K, Marczak J, Bańkowski T.
Evaluation of the significance of cystatin C
levels in patients suffering from coronary artery
disease. Adv Clin Exp Med. 2014;23:551–8.
29. Vakili H1, Mohamadian A2, Naderian
M3, Khaheshi I4. Cystatin C may not be a
precious predictor for coronary artery
disease and its severity: an area of uncertainty.
Acta Biomed. 2018 Jun 7;89(2):209-213.
30. Svensson-Färbom P1, Almgren P2, Hedblad
B2, Engström G2, Persson M3, Christensson
A4, Melander O3. Cystatin C Is Not Causally
Related to Coronary Artery Disease. PLoS
One. 2015 Jun 9;10(6):e0129269.
31. Shi GP, Sukhova GK, Grubb A, Ducharme A,
Rhode LH, Lee RT, et al. Cystatin C deficiency
in human atheroscler-osis and aortic
aneurysms. J Chin Invest. 1999;104:1191–7.